EQT

EQT is a private equity firm headquartered in Stockholm, Sweden, with additional offices across Europe, North America, and the Asia Pacific region. Founded in 1994, the firm specializes in buyouts, expansion capital, and infrastructure investments, focusing on mid-market companies with strong growth potential in various sectors, including healthcare, technology, and industrials. EQT employs a responsible ownership approach and aims to create sustainable value through active management and strategic guidance. The firm's investment strategies include private capital, real assets, credit, and public value, targeting companies with consistent cash flows and meaningful intrinsic value. EQT is also known for its expertise in the life sciences sector, having transitioned its healthcare investment arm into EQT Life Sciences, which focuses on innovative healthcare companies. The firm typically invests between €50 million and €600 million, with a preference for controlling or co-controlling stakes in its portfolio companies, which it holds for an average of four to eight years.

Sofia Ahuja

Partner

CHRISTIAN SHIN HØEGH ANDERSEN

Managing Director, Private Equity and Investment Advisory Professional

James Arrol

Managing Director, Fund Management

Teruyuki Asaoka

Managing Director

Andreas Aschenbrenner

Partner

Fouad Azzam

Partner

Fredrik Backman

Managing Director, Client Relations

Peter Balslev

Managing Director

Johann-Christoph Balzer

Partner, EQT Value-Add Infrastructure

Michael Bauer

Partner, Head of Switzerland and Co-Head of EQT's Global Healthcare Sector Team

Eirik Benzon

Managing Director, BPEA EQT Team

William Bergström

Director

Lennart Blecher

Deputy Managing Partner

Clemens Van Blitterswijk

Founder of LSP Health Economics Fund

Mark Braganza

Partner, Investment Advisory

Marcus Brennecke

Institutional Partner, Marcus is a member of the Equity Partners Investment Committee and the Portfolio Performance Review Committee

Marc Brown

Partner and Head of EQT Growth

Nicolas Brugère

Partner and Head of France

Anna Brundtland

Managing Director

Philipp Bräuer

Associate

Drew Burdon

Partner

Caspar Callerstrom

Deputy CEO

Brian Chang

Partner

Kenneth Cheong

Partner

Henry Connon

Associate, Private Equity and Investment Advisory Professional

Crosby Cook

Partner, Infrastructure and Investment Advisory Professional

Guy Cui

Partner

Nicholas Curwen

Managing Director

Alex Darden

Partner, President and Head of EQT Infrastructure Advisory Team Americas

Johan Dettel

Partner

Mads Ditlevsen

Partner and Head of EQT Partners Denmark

Asís Echániz

Partner and Head of Spain

Andreas Eichelberger

Director

Frederik Elwing

Managing Director

Leeann Emmi

Vice President

Victor Englesson

Partner, Head of Private Equity Nordic and Co-Head of Global Technology Sector

Ali Farahani

Partner

Frank Feng

Managing Director

Michael Focking

Senior Partner

Mark Fogle

Partner and Head of EQT Exeter APAC

David Forde

Partner

Per Franzén

Head of Private Capital and Deputy Managing Partner

Juho Frilander

Managing Director

Joseph Fuda

Partner, Client Relations and Capital Raising

Florian Funk

Partner, Private Equity

Maria Gaffron

Associate, Infrastructure

Guillermo Garcia-Barrero

Managing Director

Carlos Garcia-Fuster

Partner, Private Equity

Henrik Giver

Managing Director

Simon Gold

Managing Director, Client Relations and Capital Raising

Wolfgang Gorny

Partner, Private Equity

Alexander Greenbaum

Partner, Active Core Infrastructure Advisory Team and Investment Advisory Professional

Fabian Grone

Partner, Infrastructure

Albert Gustafsson

COO of Private Capital Europe and North America

Floris van Halder

Managing Director

Sean Ham

Partner and Head of Asia Pacific

Kevin Hammon

Associate

Takanobu Hara

Partner

Jerry He

Partner and Head of China, Mid Market Asia Advisory Team

Frank Heckes

Partner, Private Equity

Erika Henriksson

Partner, Private Equity

Jak Hestnes

Managing Director and Board Member

Gerran Ho

Managing Director, Mid Market Asia

Christian Horn

Managing Director

Andreas Huber

Partner

Sara Huda

Managing Director and Head of Investment Services

Johan Daniel Hylander

Managing Director

Bert Janssens

Head of Private Equity Europe and Global Co-Head of Services, Private Capital

Patrick Jaslowitzer

Managing Director

Neha Jatar

Managing Director

Bjorn Jensen

Partner

Yan Jiao

Partner

Hakan Johansson

Senior Partner

Herman Johre

Associate

Maarten de Jong

Partner, EQT Private Equity

Nathalie Kaeser

Vice President, Private Equity

Kosmo Kalliarekos

Partner

Viviana Kane

Managing Director

Masahiko Kato

Managing Director and Head of Infrastructure Japan

Matthew Kestenbaum

Managing Director

Nils Ketter

Partner

Paul Kim

Managing Director

Jörg Kinberger

Partner, Private Equity

Cillian King

Managing Director

Martijn Kleijwegt

Managing Partner

Thomas Klews

Director

John de Koning

General Partner

Kees Koolen

Partner

Vesa Koskinen

Partner, Private Equity and Head of Finland

Gleb Kozyritskiy

Managing Director

Arvindh Kumar

Partner and Co-Head of Technology Sector Team

Elias Nissilä Källström

Managing Director

Ulrich Kollensperger

Partner

Tobias Küng

Managing Director, Infrastructure

Priscilla Lam

Managing Director, Portfolio Monitoring

Lance Lan

Managing Director, Exit Management

Adam Larsson

Managing Director

Robert Latz

Managing Director

Kenneth Lau

Associate

Edward Lavish

Managing Director, Portfolio Risk and Transactions

Juliette Lee

Associate

Eu Han Lee

Partner, Debt Capital Markets

Alex Lee

Partner

Hong Yong Leong

Partner

Janice Leow

Partner

William Liang

Director of European Firm

Benjamin Lim

Director

William Lindström

Managing Director

Gebhard Littich

Managing Director

Madeleine Magnerius

Director

Paola Maleh

Partner and Head of EMEA

Francesco Malvezzi

Managing Director, Infrastructure

Tadashi Maruoka

Partner

Axel Masucci

Managing Director

Arnav Mitra

Director

Martin Mix

Managing Director

Mikael Moll

Managing Director, Public Value

Jens Moritz

Partner

Maximilian Moser

Associate

Tomasz Muszynski

Director, Private Equity

Petri Myllyneva

Partner

Pascal Noel

Managing Director

Tetsuro Onitsuka

Partner and Head of Private Equity Japan

Alex Paganini

Associate, Infrastructure

Isabel de Paoli

Partner, Healthcare

Sydney Pardey

Managing Director

Tyler Parker

Managing Director

Daniel Perez

Partner

Christopher J. Popp

Managing Director

Anne Portwich

Partner

Shane Predeek

Partner

Federico Quitadamo

Partner and Head of Italy

Vai Rajan

Head of EMEA Private Wealth Capital Raising and Director - Client Relations and Capital Raising

Thomas Rajzbaum

Managing Director and Partner, EQT Infrastructure

Hermann Rauch

Managing Director

Vera Rebanova

Partner, Client Relations and Capital Raising

Johannes Reichel

Partner

Carl Renström

Partner

Matthias Riefer

Managing Director, Private Equity

Niklas Ringby

Partner and Co-Head of Public Value Advisory Team

Patrick Rodden

Managing Director and Head of Infrastructure for Australia and New Zealand

Maxwell Roitstein

Associate

Joachim Rothe

General Partner

Isidoor Rutten

Partner

Rob Ryan

Managing Director, Market Risk

Rosa Sammon, Darlene De La

Partner and Co-Head, Client Relations and Capital Raising

Carlos Santana

Partner

Anthony Santospirito

Partner

Mika Saukkonen

Managing Director, Infrastructure

Matthew Scattarella

Partner

Philip Scheltens

Managing Partner, Dementia Fund

Paul Schrotti

Partner

Nirav Shah

Partner, EQT Value-Add Infrastructure

Hemant Sharma

Managing Director

Gordon Shaw

Partner

Christian Sinding

CEO and Managing Partner

Piyush Singhvi

Managing Director, Infrastructure

Carl Sjölund

Partner, Infrastructure

Jared Small

Managing Director

Georg Stadler

Partner, Infrastructure

Dominik Stein

Partner and Head of EQT Growth Advisory Team

Joshua Stone

Managing Director, FO Head of Strategic Initiatives

Alexander Strassburger

Managing Director

Marc-Alexander Straubinger

Managing Director

Jan Stypulkowski

Managing Director

Sang Jun Suh

Partner

Anna Sundell

Partner, Infrastructure

Miriam Tawil

Partner and Investment Advisory Professional

Michiel Thiessen

Managing Director

Elly Thio

Managing Director

Erwin A. Thompson

Partner, Infrastructure

Matteo Thun

Partner

Andrew Tirbeni

Managing Director, EQT Client Relations and Capital Raising

Wei Jian Tor

Managing Director

Juan Vargas

Partner

Felice Verduyn

Investment Manager

Jan Vesely

Partner

Marcus Wallinder

Partner and Deputy Head of Client Relations and Capital Raising

Forrest Wang

Managing Director, Private Equity

Ethan Waxman

Partner

Mark Wegter

Managing Partner

Arno de Wilde

Investor

Rickard Wilson

Managing Director

Matthias Wittkowski

Partner

Ken Wong

Partner and Head of Asia Pacific, Infrastructure

Philipp R. Wörner

Director, Private Equity

Dayea Yeon

Managing Director and Head of Private Capital Korea

Shuting You

Managing Director

James Yu

Partner and Senior Bank Relationship Manager

Julia Zhu

Managing Director

Fredrik Åtting

Partner

John Österlund

Managing Director, Infrastructure

Stephan Leithner Ph.D

Partner

René Kuijten Ph.D

Managing Partner

Past deals in Dental

3Shape

Private Equity Round in 2021
3Shape creates 3D scanners and CAD/CAM software solutions to improve patient care for dental and audiology professionals around the world.

IVC Evidensia

Private Equity Round in 2021
Provider of veterinary care services with clinics spread across Europe. The company has an expansive network of clinics, hospitals, and out-of-hour centers, thereby serving pet owners and guiding them on balanced nutrition for every animal, regardless of breed, age, and gender.

Galderma

Acquisition in 2019
Galderma S.A. is a global company specializing in the manufacture and distribution of medical, consumer skin health, and dermatology products. Founded in 1981 and headquartered in Lausanne, Switzerland, Galderma offers a wide range of solutions including prescription medicines, medical aesthetics, and skincare products. Its extensive product portfolio addresses various dermatological conditions such as acne, rosacea, psoriasis, and skin cancer, with well-known brands like Epiduo®, Differin®, and Restylane®. The company operates through a network of 33 wholly-owned affiliates and distributors in approximately 80 countries, employing around 6,600 people. Galderma emphasizes innovation in meeting the dermatological needs of individuals and healthcare professionals, with research and development, and manufacturing sites located across multiple regions including Europe, Asia-Pacific, and the Americas.

Simplify Medical

Series B in 2018
Simplify Medical, Inc. is a medical device company that specializes in the design, development, and manufacture of cervical and lumbar artificial discs for spinal use. The company's flagship product, the Simplify Disc, is a non-metallic, motion-preserving cervical artificial disc that is compatible with magnetic resonance imaging (MRI), eliminating the need for CT imaging and reducing patient exposure to ionizing radiation. This product is specifically intended for skeletally mature patients undergoing reconstruction of a single cervical disc following discectomy for conditions such as radiculopathy. Simplify Medical markets its innovative products through distributors in various regions, including the United Kingdom and Germany. Founded in 2013 and originally known as Simplify Delaware, Inc., the company rebranded to Simplify Medical, Inc. in 2015 and is headquartered in Sunnyvale, California.

Xeltis

Series C in 2017
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Dentconnect

Acquisition in 2017
DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.

Simplify Medical

Series B in 2017
Simplify Medical, Inc. is a medical device company that specializes in the design, development, and manufacture of cervical and lumbar artificial discs for spinal use. The company's flagship product, the Simplify Disc, is a non-metallic, motion-preserving cervical artificial disc that is compatible with magnetic resonance imaging (MRI), eliminating the need for CT imaging and reducing patient exposure to ionizing radiation. This product is specifically intended for skeletally mature patients undergoing reconstruction of a single cervical disc following discectomy for conditions such as radiculopathy. Simplify Medical markets its innovative products through distributors in various regions, including the United Kingdom and Germany. Founded in 2013 and originally known as Simplify Delaware, Inc., the company rebranded to Simplify Medical, Inc. in 2015 and is headquartered in Sunnyvale, California.

Fertin Pharma

Acquisition in 2016
Fertin Pharma, based in Vejle, Denmark, specializes in the development and manufacturing of innovative pharmaceutical and nutraceutical chewing gum products. The company has established itself as a preferred B2B partner for nicotine chewing gum through collaborations with leading global pharmaceutical firms. Fertin Pharma focuses on oral and intra-oral delivery systems, including extruded gum for Nicotine Replacement Therapy (NRT) and applications in oral care, gastrointestinal management, pain relief, and allergy treatment. By emphasizing high quality and functionality, the company enables healthcare providers to enhance the effectiveness of active ingredients while maintaining an optimal consumer experience. As a family-owned business with a strong legacy in the chewing gum industry, Fertin Pharma is committed to fostering open and professional relationships with its partners.

Rotation Medical

Series B in 2016
Rotation Medical Inc. specializes in the development of a minimally invasive rotator cuff implant system aimed at treating rotator cuff disease. The company's innovative implant consists of a collagen scaffold designed to be affixed to damaged rotator cuff tendons, providing effective management and protection for tendon injuries. This system offers a surgical solution for patients with small rotator cuff tears and serves as an additional protective layer for larger tears. Founded in 2006 and headquartered in Plymouth, Minnesota, Rotation Medical was previously known as Denali Medical Inc. and rebranded in March 2010. As of December 2017, the company operates as a subsidiary of Smith & Nephew plc.

Xeltis

Series B in 2015
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Xeltis

Series B in 2014
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.

Evidensia Djursjukvard

Acquisition in 2014
Evidensia Djursjukvård AB owns and operates veterinary hospitals and clinics in Sweden, Norway, Denmark, Finland, Holland, Germany, and Switzerland.

Rotation Medical

Series B in 2014
Rotation Medical Inc. specializes in the development of a minimally invasive rotator cuff implant system aimed at treating rotator cuff disease. The company's innovative implant consists of a collagen scaffold designed to be affixed to damaged rotator cuff tendons, providing effective management and protection for tendon injuries. This system offers a surgical solution for patients with small rotator cuff tears and serves as an additional protective layer for larger tears. Founded in 2006 and headquartered in Plymouth, Minnesota, Rotation Medical was previously known as Denali Medical Inc. and rebranded in March 2010. As of December 2017, the company operates as a subsidiary of Smith & Nephew plc.

Terveystalo Healthcare

Acquisition in 2013
Terveystalo is the largest healthcare service company in Finland. We offer a wide range of health, occupational health, medical care and research services as well as dental services in nearly 200 locations in more than 70 locations throughout Finland.

Swiss Smile

Private Equity Round in 2013
Swiss Smile Holding AG operates a network of dental competence centers, providing a comprehensive range of dental services including aesthetic dentistry, bleaching, implantology, orthodontics, oral surgery, endodontics, pediatric dentistry, periodontology, and professional teeth cleaning. Established in 2002, the company caters to both local and international patients, with centers located in various Swiss cities such as Zurich, Baden, St. Moritz, Suhr, and Winterthur, as well as international locations including Bengaluru, Moscow, and London. Swiss Smile also offers dental hygiene products such as whitening toothpastes, toothbrushes, and interdental brushes. Additionally, the company emphasizes preventive care and education, offering dentistry classes in schools to promote oral health awareness.

Dako

Acquisition in 2007
Dako Denmark A/S specializes in providing reagents, instruments, and software for cancer diagnostics, primarily serving hospital and research laboratories globally. The company offers a wide range of pathology products, including antibodies, pharmacodiagnostic kits, and specialized staining instruments. These tools are essential for pathologists conducting in vitro diagnostics to identify cancer and other chronic diseases through tissue samples. Additionally, Dako produces flow cytometry products, which assist in analyzing cells in blood and other fluids for diagnosing conditions such as leukemia and lymphoma. The company also develops antibodies used to measure protein concentrations in various bodily fluids. Established in 1966 and headquartered in Glostrup, Denmark, Dako has formed collaborations with companies like Genentech and Roche for the clinical development of diagnostic tests. In 2012, Dako was acquired by Agilent Technologies.

KaVo Kerr

Debt Financing in 2005
KaVo Kerr is a cohesive organization comprised of two global leaders, united to provide dental excellence and serve as a single premier partner for the dental community. For more than 100 years, KaVo has focused on innovation and quality in dental products and services, building an outstanding reputation among dentists, dental technicians and dental hygienists. KaVo offers a comprehensive product portfolio that includes imaging, treatment units, instrumentation, laboratory equipment and educational aids. In product development, service and support, customers around the world see and experience KaVo’s ongoing commitment to Dental Excellence.

Sirona Dental System

Acquisition in 2003
Sirona Dental System is a global leader in dental technology, specializing in the manufacture and distribution of a wide range of dental products. The company offers solutions tailored for dental practices, clinics, and laboratories, including dental laboratory products, needles, x-ray products, implants, removable prosthetics, and various disposable medical devices. By focusing on customer needs, Sirona aims to enhance the efficiency and effectiveness of dental care delivery, positioning itself as a key player in the dental industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.